FilingReader Intelligence

Meihua Biotech completes acquisition of Kirin’s amino acid and HMO businesses

October 22, 2025 at 10:09 AM UTCBy FilingReader AI

Meihua Biotech Group Co., Ltd. and its subsidiary Plum Biotechnology Group Pte. Ltd. have completed the acquisition of Kirin Holdings Company, Limited's food amino acid, pharmaceutical amino acid, and human milk oligosaccharide (HMO) businesses. The initial agreement, signed on November 22, 2024, set the acquisition price at JPY 10.5 bn. Following the asset transfer on July 1, 2025, and adjustments for cash reserves (JPY 11.3 bn) and working capital, the final transaction value is approximately JPY 16.8 bn.

An independent assessment valued the acquired assets' shareholders' equity at CNY 1,625,705,900 based on June 30, 2025. This valuation implies a significant adjustment from the book value, with total assets decreasing by 28.29% and shareholders' equity decreasing by 30.48%.

As a result of the acquisition, Meihua Biotech expects to record a non-operating income of approximately CNY 780m in its consolidated profit statement for the 2025 financial year. This gain is attributed to the acquisition cost being less than the fair value of the identifiable net assets acquired, as per accounting standards for business combinations. The company advises investors to exercise caution and monitor further disclosures.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Meihua Holdings Group publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →